Bringing the Oncology Community Together

Dr. Munster on Vorinostat Plus Tamoxifen for Breast Cancer

Pamela Munster, MD
Published Online: Tuesday, October 23, 2012
Pamela Munster, MD, Director, Early Phase Clinical Trials Unit and Leader, Developmental Therapeutics Program, UCSF Helen Diller Family Comprehensive Cancer Center, discusses results from a phase II study that examined the histone deacetylase (HDAC) inhibitor vorinostat in combination with tamoxifen for patients with hormone therapy-resistant breast cancer.

The trial enrolled 43 patients with estrogen receptor-positive metastatic breast cancer who had developed resistance to endocrine therapy, including tamoxifen and aromatase inhibitors. The trial also evaluated HDAC2 expression and histone acetylation, as possible markers.

The trial found that 19% of patients treated with vorinostat plus tamoxifen experienced tumor shrinkage and 21% had stable disease at 6 months. However, the examination of HDAC2 and histone acetylation showed that only approximately 55% of patients responded to treatment with the combination.

Munster adds that future trials examining the combination will implement testing for HDAC2 expression and histone hyperacetylation as part of the inclusion criteria.

Related Articles
Experts Debate Utility of Genomic Profiling in Daily Practice
Although the potential for next-generation sequencing of breast cancer tumors to improve treatment strategies is widely recognized, questions swirl about the optimal use of such increasingly available technologies in clinical practice for today’s patients.
AR Findings Highlight Detailed Tumor-Profiling Study
A wide-ranging analysis of more than 5500 breast cancer tumors that combined genomic and protein expression testing has identified promising targets to explore for treating patients with poor prognoses, with particularly notable findings involving androgen receptor (AR) expression
Phase III Clinical Trials in HER2-Positive Breast Cancer
Expert panelists explore several large clinical trials examining therapies for patients with HER2-positive breast cancer that are currently ongoing or have recently completed.
Most Popular Right Now
More Reading
External Resources

American Journal of Managed Care
HCPLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
TargetedOnc
OncLive Resources

Archives
Blogs
OncLive TV
Oncology Nurses
Publications
Specialties
Web Exclusives


About Us
Advertise
Advisory Board
Contact Us
Forgot Password
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.